164 related articles for article (PubMed ID: 21591726)
1. Formation of stable hydrophilic C60 nanoparticles by 2-hydroxypropyl-β-cyclodextrin.
Iohara D; Hirayama F; Higashi K; Yamamoto K; Uekama K
Mol Pharm; 2011 Aug; 8(4):1276-84. PubMed ID: 21591726
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of photodynamic activity of C60/2-hydroxypropyl-β-cyclodextrin nanoparticles.
Iohara D; Hiratsuka M; Hirayama F; Takeshita K; Motoyama K; Arima H; Uekama K
J Pharm Sci; 2012 Sep; 101(9):3390-7. PubMed ID: 22228093
[TBL] [Abstract][Full Text] [Related]
3. Some pharmaceutical and inclusion properties of 2-hydroxybutyl-β-cyclodextrin derivative.
Ishiguro T; Morishita E; Iohara D; Hirayama F; Wada K; Motoyama K; Arima H; Uekama K
Int J Pharm; 2011 Oct; 419(1-2):161-9. PubMed ID: 21839823
[TBL] [Abstract][Full Text] [Related]
4. Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin.
Kim JH; Lee SK; Ki MH; Choi WK; Ahn SK; Shin HJ; Hong CI
Int J Pharm; 2004 Mar; 272(1-2):79-89. PubMed ID: 15019071
[TBL] [Abstract][Full Text] [Related]
5. NMR spectroscopic characterization of metoprolol/cyclodextrin complexes in aqueous solution: cavity size dependency.
Ikeda Y; Hirayama F; Arima H; Uekama K; Yoshitake Y; Harano K
J Pharm Sci; 2004 Jul; 93(7):1659-71. PubMed ID: 15176056
[TBL] [Abstract][Full Text] [Related]
6. A stable water-soluble tetramethylbenzidine-2-hydroxypropyl-beta-cyclodextrin inclusion complex and its applications in enzyme assays.
Cattaneo MV; Luong JH
Anal Biochem; 1994 Dec; 223(2):313-20. PubMed ID: 7887477
[TBL] [Abstract][Full Text] [Related]
7. Sildenafil/cyclodextrin complexation: stability constants, thermodynamics, and guest-host interactions probed by 1H NMR and molecular modeling studies.
Al Omari MM; Zughul MB; Davies JE; Badwan AA
J Pharm Biomed Anal; 2006 Jun; 41(3):857-65. PubMed ID: 16527440
[TBL] [Abstract][Full Text] [Related]
8. Preparation of hydrophilic C60(OH)10/2-hydroxypropyl-β-cyclodextrin nanoparticles for the treatment of a liver injury induced by an overdose of acetaminophen.
Umezaki Y; Iohara D; Anraku M; Ishitsuka Y; Irie T; Uekama K; Hirayama F
Biomaterials; 2015 Mar; 45():115-23. PubMed ID: 25662501
[TBL] [Abstract][Full Text] [Related]
9. Encapsulation and Stabilization of α-Lipoic Acid in Cyclodextrin Inclusion Complex Electrospun Nanofibers: Antioxidant and Fast-Dissolving α-Lipoic Acid/Cyclodextrin Nanofibrous Webs.
Celebioglu A; Uyar T
J Agric Food Chem; 2019 Nov; 67(47):13093-13107. PubMed ID: 31693349
[TBL] [Abstract][Full Text] [Related]
10. UV-vis and FTIR-ATR characterization of 9-fluorenon-2-carboxyester/(2-hydroxypropyl)-beta-cyclodextrin inclusion complex.
Stancanelli R; Ficarra R; Cannavà C; Guardo M; Calabrò ML; Ficarra P; Ottanà R; Maccari R; Crupi V; Majolino D; Venuti V
J Pharm Biomed Anal; 2008 Aug; 47(4-5):704-9. PubMed ID: 18400444
[TBL] [Abstract][Full Text] [Related]
11. Influence of modified cyclodextrins on solubility and percutaneous absorption of celecoxib through human skin.
Ventura CA; Tommasini S; Falcone A; Giannone I; Paolino D; Sdrafkakis V; Mondello MR; Puglisi G
Int J Pharm; 2006 May; 314(1):37-45. PubMed ID: 16581211
[TBL] [Abstract][Full Text] [Related]
12. Two-dimensional 13C-1H heteronuclear correlation NMR spectroscopic studies for the inclusion complex of cyclomaltoheptaose (beta-cyclodextrin) with a new Helicobacter pylori eradicating agent (TG44) in the amorphous state.
Anzai K; Kono H; Mizoguchi J; Yanagi T; Hirayama F; Arima H; Uekama K
Carbohydr Res; 2006 Mar; 341(4):499-506. PubMed ID: 16427035
[TBL] [Abstract][Full Text] [Related]
13. Improvement of solubility and oral bioavailability of 2-(N-cyanoimino)-5-[(E)-4-styrylbenzylidene]-4-oxothiazolidine (FPFS-410) with antidiabetic and lipid-lowering activities in dogs by 2-hydroxypropyl-beta-cyclodextrin.
Hara T; Hirayama F; Arima H; Yamaguchi Y; Uekama K
Chem Pharm Bull (Tokyo); 2006 Mar; 54(3):344-9. PubMed ID: 16508189
[TBL] [Abstract][Full Text] [Related]
14. Solid-state 13C nuclear magnetic resonance spectroscopic study on amorphous solid complexes of tolbutamide with 2-hydroxypropyl-alpha- and -beta-cyclodextrins.
Kimura K; Hirayama F; Arima H; Uekama K
Pharm Res; 1999 Nov; 16(11):1729-34. PubMed ID: 10571279
[TBL] [Abstract][Full Text] [Related]
15. Controlled release of a water-soluble drug, captopril, by a combination of hydrophilic and hydrophobic cyclodextrin derivatives.
Ikeda Y; Kimura K; Hirayama F; Arima H; Uekama K
J Control Release; 2000 May; 66(2-3):271-80. PubMed ID: 10742586
[TBL] [Abstract][Full Text] [Related]
16. Curve-fitting FTIR studies of loratadine/hydroxypropyl-beta-cyclodextrin inclusion complex induced by co-grinding process.
Lin SY; Hsu CH; Sheu MT
J Pharm Biomed Anal; 2010 Nov; 53(3):799-803. PubMed ID: 20619996
[TBL] [Abstract][Full Text] [Related]
17. Inclusion complex formation of captopril with alpha- and beta-cyclodextrins in aqueous solution: NMR spectroscopic and molecular dynamic studies.
Ikeda Y; Motoune S; Matsuoka T; Arima H; Hirayama F; Uekama K
J Pharm Sci; 2002 Nov; 91(11):2390-8. PubMed ID: 12379924
[TBL] [Abstract][Full Text] [Related]
18. Molecular simulation of hydroxypropyl-beta-cyclodextrin with hydrophobic selective Cox-II chemopreventive agent using host-guest phenomena.
Sinha VR; Nanda A; Chadha R; Goel H
Acta Pol Pharm; 2011; 68(4):585-92. PubMed ID: 21796941
[TBL] [Abstract][Full Text] [Related]
19. Cyclodextrins as carriers for kavalactones in aqueous media: spectroscopic characterization of (S)-7,8-dihydrokavain and beta-cyclodextrin inclusion complex.
Pescitelli G; Bilia AR; Bergonzi MC; Vincieri FF; Di Bari L
J Pharm Biomed Anal; 2010 Aug; 52(4):479-83. PubMed ID: 20185265
[TBL] [Abstract][Full Text] [Related]
20. Inclusion of Paracetamol into β-cyclodextrin nanocavities in solution and in the solid state.
El-Kemary M; Sobhy S; El-Daly S; Abdel-Shafi A
Spectrochim Acta A Mol Biomol Spectrosc; 2011 Sep; 79(5):1904-8. PubMed ID: 21703916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
